The predictive role of ERCC1 status in oxaliplatin based neoadjuvant therapy for Metastatic Colorectal Cancer (mCRC) to the liver

Ravit Geva; Sivan Shamai; Eli Brazowsky; Michael Paoulas; Mendi Ben-Haim; Elaine Johnstone; Beny Alex; Einat Shacham-Shmueli

doi:10.3109/07357907.2014.998834

The predictive role of ERCC1 status in oxaliplatin based neoadjuvant therapy for Metastatic Colorectal Cancer (mCRC) to the liver

Ravit Geva^*
, Sivan Shamai
, Eli Brazowsky
, Michael Paoulas
, Mendi Ben-Haim
, Elaine Johnstone
, Beny Alex
, Einat Shacham-Shmueli

^*Corresponding author for this work

Tel Aviv Sourasky Medical Center
University of Oxford
Tel Aviv University
Rambam Health Care Campus Israel
Technion-Israel Institute of Technology

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

Increased expression of excision repair cross-complementing 1 (ERCC1) in mCRC patients could be related to their response to Oxaliplatin based chemotherapy. We evaluated ERCC1 mRNA expression levels in primary bowel and liver metastases of 51 patients, and correlated with pathologic parameters and clinical outcomes. A significant negative correlation was detected between primary tumor ERCC1 and both the extent of clear surgical margins (P = 0.0011) and the percent of liver metastasis necrosis (P = 0.0167). No relationship was observed between ERCC1 expression and survival. Further study is needed to assess the promising role of ERCC1 expression as a predictive marker benefiting subgroups for Oxaliplatin.

Original language	English
Pages (from-to)	89-97
Number of pages	9
Journal	Cancer Investigation
Volume	33
Issue number	4
DOIs	https://doi.org/10.3109/07357907.2014.998834
State	Published - 21 Apr 2015
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

ERCC1
Metastatic colorectal cancer
Oxaliplatin

Access to Document

10.3109/07357907.2014.998834

Cite this

@article{ee61c88617604d6dba624db2836aa4e4,

title = "The predictive role of ERCC1 status in oxaliplatin based neoadjuvant therapy for Metastatic Colorectal Cancer (mCRC) to the liver",

abstract = "Increased expression of excision repair cross-complementing 1 (ERCC1) in mCRC patients could be related to their response to Oxaliplatin based chemotherapy. We evaluated ERCC1 mRNA expression levels in primary bowel and liver metastases of 51 patients, and correlated with pathologic parameters and clinical outcomes. A significant negative correlation was detected between primary tumor ERCC1 and both the extent of clear surgical margins (P = 0.0011) and the percent of liver metastasis necrosis (P = 0.0167). No relationship was observed between ERCC1 expression and survival. Further study is needed to assess the promising role of ERCC1 expression as a predictive marker benefiting subgroups for Oxaliplatin.",

keywords = "ERCC1, Metastatic colorectal cancer, Oxaliplatin",

author = "Ravit Geva and Sivan Shamai and Eli Brazowsky and Michael Paoulas and Mendi Ben-Haim and Elaine Johnstone and Beny Alex and Einat Shacham-Shmueli",

note = "Publisher Copyright: {\textcopyright} 2015 Informa Healthcare USA, Inc.",

year = "2015",

month = apr,

day = "21",

doi = "10.3109/07357907.2014.998834",

language = "אנגלית",

volume = "33",

pages = "89--97",

journal = "Cancer Investigation",

issn = "0735-7907",

publisher = "Taylor \& Francis Group LLC Philadelphia",

number = "4",

}

TY - JOUR

T1 - The predictive role of ERCC1 status in oxaliplatin based neoadjuvant therapy for Metastatic Colorectal Cancer (mCRC) to the liver

AU - Geva, Ravit

AU - Shamai, Sivan

AU - Brazowsky, Eli

AU - Paoulas, Michael

AU - Ben-Haim, Mendi

AU - Johnstone, Elaine

AU - Alex, Beny

AU - Shacham-Shmueli, Einat

PY - 2015/4/21

Y1 - 2015/4/21

N2 - Increased expression of excision repair cross-complementing 1 (ERCC1) in mCRC patients could be related to their response to Oxaliplatin based chemotherapy. We evaluated ERCC1 mRNA expression levels in primary bowel and liver metastases of 51 patients, and correlated with pathologic parameters and clinical outcomes. A significant negative correlation was detected between primary tumor ERCC1 and both the extent of clear surgical margins (P = 0.0011) and the percent of liver metastasis necrosis (P = 0.0167). No relationship was observed between ERCC1 expression and survival. Further study is needed to assess the promising role of ERCC1 expression as a predictive marker benefiting subgroups for Oxaliplatin.

AB - Increased expression of excision repair cross-complementing 1 (ERCC1) in mCRC patients could be related to their response to Oxaliplatin based chemotherapy. We evaluated ERCC1 mRNA expression levels in primary bowel and liver metastases of 51 patients, and correlated with pathologic parameters and clinical outcomes. A significant negative correlation was detected between primary tumor ERCC1 and both the extent of clear surgical margins (P = 0.0011) and the percent of liver metastasis necrosis (P = 0.0167). No relationship was observed between ERCC1 expression and survival. Further study is needed to assess the promising role of ERCC1 expression as a predictive marker benefiting subgroups for Oxaliplatin.

KW - ERCC1

KW - Metastatic colorectal cancer

KW - Oxaliplatin

UR - https://www.scopus.com/pages/publications/84930011094

U2 - 10.3109/07357907.2014.998834

DO - 10.3109/07357907.2014.998834

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 25723812

AN - SCOPUS:84930011094

SN - 0735-7907

VL - 33

SP - 89

EP - 97

JO - Cancer Investigation

JF - Cancer Investigation

IS - 4

ER -

The predictive role of ERCC1 status in oxaliplatin based neoadjuvant therapy for Metastatic Colorectal Cancer (mCRC) to the liver

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this